Reduced mu opioid receptor availability in schizophrenia revealed with [11C]-carfentanil positron emission tomographic Imaging.

Change log
Myers, Jim 
Reis Marques, Tiago 
Howes, Oliver D 

Negative symptoms, such as amotivation and anhedonia, are a major cause of functional impairment in schizophrenia. There are currently no licensed treatments for negative symptoms, highlighting the need to understand the molecular mechanisms underlying them. Mu-opioid receptors (MOR) in the striatum play a key role in hedonic processing and reward function and are reduced post-mortem in schizophrenia. However, it is unknown if mu-opioid receptor availability is altered in-vivo or related to negative symptoms in schizophrenia. Using [11 C]-carfentanil positron emission tomography (PET) scans in 19 schizophrenia patients and 20 age-matched healthy controls, here we show a significantly lower MOR availability in patients with schizophrenia in the striatum (Cohen's d = 0.7), and the hedonic network. In addition, we report a marked global increase in inter-regional covariance of MOR availability in schizophrenia, largely due to increased cortical-subcortical covariance.

Adult, Analgesics, Opioid, Brain, Carbon Radioisotopes, Case-Control Studies, Female, Fentanyl, Healthy Volunteers, Humans, Male, Positron-Emission Tomography, Radioactive Tracers, Receptors, Opioid, mu, Schizophrenia
Journal Title
Nat Commun
Conference Name
Journal ISSN
Volume Title
Springer Science and Business Media LLC